(Canavan Disease)(Press Release)
Stephanos Karakasidis serves as the Executive Director, Head of Quality at Myrtelle, where he oversees all quality systems, processes, and initiatives for the organization as well as implementation of a risk-based audit program, CAPA management, audits, and quality metrics. He joined the Company in 2021, bringing more than 15 years of experience in various roles in the biotech and Contract Testing Organizations. Most recently, he served as the Director of Quality Control, at the University of Pennsylvania’s Gene Therapy Program, where he oversaw the characterization testing and release of viral vectors. Previously, he has held positions of increasing responsibilities at WuXi Advanced Therapies and Charles River Laboratories.
Stephanos obtained his B.S. in Biology from Guilford College and an M.S. in Biochemistry and Molecular Biology from Georgetown University. His passions include the rare disease arena, with the focus on making difference in people’s life through development of novel therapies.
In his spare time, he likes to go hiking with his wife and two boys, traveling back to Greece to visit family and friends, and reading.